379 related articles for article (PubMed ID: 22884399)
41. Data-driven grading of brain gliomas: a multiparametric MR imaging study.
Caulo M; Panara V; Tortora D; Mattei PA; Briganti C; Pravatà E; Salice S; Cotroneo AR; Tartaro A
Radiology; 2014 Aug; 272(2):494-503. PubMed ID: 24661247
[TBL] [Abstract][Full Text] [Related]
42. Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.
Gunjur A; Lau E; Taouk Y; Ryan G
J Med Imaging Radiat Oncol; 2011 Dec; 55(6):603-10. PubMed ID: 22141608
[TBL] [Abstract][Full Text] [Related]
43. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Yamaguchi S; Tanino M; Murata J; Houkin K
Brain Tumor Pathol; 2013 Apr; 30(2):67-72. PubMed ID: 22752663
[TBL] [Abstract][Full Text] [Related]
44. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
45. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
46. Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients.
Yoo RE; Choi SH
Magn Reson Med Sci; 2016; 15(2):165-77. PubMed ID: 26726012
[TBL] [Abstract][Full Text] [Related]
47. Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis.
Abbasi AW; Westerlaan HE; Holtman GA; Aden KM; van Laar PJ; van der Hoorn A
Clin Neuroradiol; 2018 Sep; 28(3):401-411. PubMed ID: 28466127
[TBL] [Abstract][Full Text] [Related]
48. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
[TBL] [Abstract][Full Text] [Related]
49. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
[TBL] [Abstract][Full Text] [Related]
50. Pseudoprogression of malignant glioma in Chinese patients receiving concomitant chemoradiotherapy.
Chan DT; Ng RY; Siu DY; Tang P; Kam MK; Ma BB; Wong GK; Ng SC; Pang JC; Lau CK; Zhu XL; Ng HK; Poon WS
Hong Kong Med J; 2012 Jun; 18(3):221-5. PubMed ID: 22665686
[TBL] [Abstract][Full Text] [Related]
51. Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Yaman E; Buyukberber S; Benekli M; Oner Y; Coskun U; Akmansu M; Ozturk B; Kaya AO; Uncu D; Yildiz R
Clin Neurol Neurosurg; 2010 Oct; 112(8):662-7. PubMed ID: 20627551
[TBL] [Abstract][Full Text] [Related]
52. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.
Zeng QS; Li CF; Liu H; Zhen JH; Feng DC
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):151-8. PubMed ID: 17289287
[TBL] [Abstract][Full Text] [Related]
53. Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Perry LA; Korfiatis P; Agrawal JP; Erickson BJ
Neuroradiology; 2018 Jan; 60(1):35-42. PubMed ID: 29103145
[TBL] [Abstract][Full Text] [Related]
54. Differentiation of high-grade from low-grade diffuse gliomas using diffusion-weighted imaging: a comparative study of mono-, bi-, and stretched-exponential diffusion models.
Kusunoki M; Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Hata N; Mizoguchi M; Iihara K; Suzuki SO; Iwaki T; Akamine Y; Hiwatashi A
Neuroradiology; 2020 Jul; 62(7):815-823. PubMed ID: 32424712
[TBL] [Abstract][Full Text] [Related]
55. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
[TBL] [Abstract][Full Text] [Related]
56. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
McConville P; Hambardzumyan D; Moody JB; Leopold WR; Kreger AR; Woolliscroft MJ; Rehemtulla A; Ross BD; Holland EC
Clin Cancer Res; 2007 May; 13(10):2897-904. PubMed ID: 17504989
[TBL] [Abstract][Full Text] [Related]
57. Minimum apparent diffusion coefficients in the evaluation of brain tumors.
Kitis O; Altay H; Calli C; Yunten N; Akalin T; Yurtseven T
Eur J Radiol; 2005 Sep; 55(3):393-400. PubMed ID: 16129247
[TBL] [Abstract][Full Text] [Related]
58. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
59. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
60. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI.
Werner JM; Stoffels G; Lichtenstein T; Borggrefe J; Lohmann P; Ceccon G; Shah NJ; Fink GR; Langen KJ; Kabbasch C; Galldiks N
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1889-1901. PubMed ID: 31203420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
